Equities

Ardelyx Inc

Ardelyx Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.59
  • Today's Change-0.305 / -6.23%
  • Shares traded6.14m
  • 1 Year change+28.93%
  • Beta0.7966
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Ardelyx Inc grew revenues 138.61% from 52.16m to 124.46m while net income improved from a loss of 67.21m to a smaller loss of 66.07m.
Gross margin85.16%
Net profit margin-28.82%
Operating margin-25.44%
Return on assets-22.09%
Return on equity-41.54%
Return on investment-26.72%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Ardelyx Inc fell by 74.67m. Cash Flow from Financing totalled 146.30m or 117.55% of revenues. In addition the company used 89.72m for operations while cash used for investing totalled 131.25m.
Cash flow per share-0.302
Price/Cash flow per share--
Book value per share0.6682
Tangible book value per share0.6682
More ▼

Balance sheet in USDView more

Ardelyx Inc has a Debt to Total Capital ratio of 38.88%, a higher figure than the previous year's 14.24%.
Current ratio4.03
Quick ratio3.87
Total debt/total equity0.6362
Total debt/total capital0.3888
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.